# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Pablo Neruda (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML051-SYN
- Date: 2026-06-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marisol Fairweather-Diaz, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review: biopsy and staging results; medical oncology seen today. **S**

## History of present illness

Mr. Neruda returns two weeks after his first visit, with a professional Spanish interpreter. In the past ten days he had an MRI of the prostate, a targeted biopsy at the urology practice, a CT scan, a bone scan and a PSMA PET/CT. The results were explained to him this morning by Dr. Okonkwo-Lund of medical oncology and again today: prostate cancer, Gleason 4+4, that has spread to two lymph nodes in the pelvis and to two places in the bones, the right hip bone and the lowest lumbar vertebra, with nothing in the lungs, liver or other organs. He chose, after hearing the options, to start apalutamide today, with a leuprolide injection in one week and radiotherapy to the prostate in about six weeks. His blood was drawn today for germline genetic testing after counseling. He had his bone density scan this morning. The right hip pain is a little better on acetaminophen, 5 of 10 at worst, and still wakes him some nights; he has no leg weakness, numbness, or change in bladder or bowel control. His urinary symptoms are unchanged. He feels the news is hard but says he would rather know. He wants to keep writing every morning and to continue his duties. **S**

| Element | Detail |
|---|---|
| Diagnosis | Prostate adenocarcinoma, Gleason 4+4 (Grade Group 4), 9 of 14 cores |
| Staging | Two pelvic lymph nodes and two bone metastases (right ilium, L5); no visceral disease: low volume |
| Decision | Apalutamide from today, leuprolide in one week, radiotherapy to the prostate; no docetaxel |
| Starting today | Apalutamide 240 mg daily; cholecalciferol 2000 units daily |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No weight loss, fever or night sweats |
| Genitourinary | Positive | Frequency, weak stream and nocturia three times, unchanged; no blood in the urine |
| Musculoskeletal | Positive | Right hip and low back pain, 5 of 10 at worst on acetaminophen |
| Neurological | Negative | No leg weakness, numbness or saddle numbness; no change in bladder or bowel control |
| Psychiatric | Negative | Worried but coping; PHQ-2 score 1 |

5 systems reviewed. **S**

## Current medications

- Amlodipine 5 mg oral tablet, one tablet daily **S**
- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone pain **S**
- Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without food **S**
- Cholecalciferol (vitamin D3) 2000 units (0.05 mg) oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 142/86 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 92 kg; BMI 29 kg/m². All vital signs are synthetic.

Femoral neck T-score (DXA): -2.1 (low); Lumbar spine T-score, L1 to L4 (DXA): -1.4 (low); PHQ-2: 1; Pain, 0 to 10: 5. All results are synthetic.

## Change since baseline

- Pain, 0 to 10: 6 at baseline, 5 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; walks without help, favoring the right hip slightly |
| Cardiovascular | Regular rhythm; blood pressure 142/86 mm Hg; no ankle swelling |
| Musculoskeletal | Tender over the right iliac crest; no midline spinal tenderness |
| Neurological | Strength 5 of 5 in both legs; sensation and knee and ankle reflexes normal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Metastatic hormone-sensitive prostate cancer, Grade Group 4, cT3a N1 M1b, low volume** (C61). De novo metastatic disease, low volume on conventional imaging (two bone metastases, both in the spine and pelvis, and no visceral disease), confirmed by PSMA PET/CT. The plan follows the consultation today: androgen deprivation with an androgen receptor pathway inhibitor, plus radiotherapy to the prostate for low-volume disease. Docetaxel is not added, because its survival benefit is in high-volume disease. **S**
   - Apalutamide 240 mg once daily from today.
   - Leuprolide 22.5 mg in one week at the oncology clinic, then every twelve weeks; apalutamide started a week before covers the testosterone flare.
   - Radiotherapy to the prostate, 55 Gy in 20 fractions, about six weeks after starting.
   - Germline testing sent today; somatic testing of the biopsy tissue requested.
2. **Bone metastases (right ilium, L5)** (C79.51). Pain improving on acetaminophen; no signs of spinal cord compression. Androgen deprivation usually eases bone pain within weeks. **S**
   - Acetaminophen 1000 mg up to three times a day.
   - Warning signs of cord compression reviewed again in Spanish, with a written card.
3. **Low bone mass before androgen deprivation** (M85.89). Femoral neck T-score -2.1 and L1 to L4 -1.4. FRAX, counting androgen deprivation as a cause of secondary osteoporosis, gives a ten-year hip fracture risk of 3.4 percent and a major osteoporotic fracture risk of 13 percent; the hip risk is above the 3 percent threshold for a bone-protective drug. **S**
   - Dental examination before denosumab.
   - Denosumab 60 mg every six months, the osteoporosis dose, once calcium is confirmed normal and vitamin D is being replaced.
   - Calcium 1000 to 1200 mg a day from food; walking and resistance exercise.
4. **Vitamin D insufficiency** (E55.9). 25-hydroxyvitamin D 22 ng/mL. **S**
   - Cholecalciferol 2000 units daily from today; recheck in four weeks before denosumab.
5. **Hypertension** (I10). 142/86 mm Hg, above goal. Apalutamide is a strong CYP3A4 inducer and is expected to lower amlodipine levels. **S**
   - Blood pressure at the four-week visit; amlodipine dose to be adjusted then.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | PSA before treatment | Baseline, then every 3 to 6 months on androgen deprivation | Up to date | 46.8 ng/mL at the first visit |
| Laboratory | Testosterone | Baseline, then every 3 to 6 months on androgen deprivation (target below 50 ng/dL) | Up to date | 468 ng/dL at the first visit |
| Laboratory | Blood count, chemistry, alkaline phosphatase and LDH | Baseline in metastatic disease | Up to date | Hemoglobin 13.6 g/dL; creatinine 0.96 mg/dL; alkaline phosphatase 168 U/L (raised); LDH 208 U/L; calcium 9.6 mg/dL |
| Laboratory | TSH before apalutamide | Baseline, then periodically on apalutamide | Ordered | Ordered today before the first dose |
| Laboratory | Hemoglobin A1c and lipid panel | Baseline and yearly on androgen deprivation | Up to date | A1c 5.9 percent and LDL 140 mg/dL at the first visit |
| Laboratory | Calcium and 25-hydroxyvitamin D | Baseline and periodically on androgen deprivation and bone-protective drugs | Up to date | Calcium 9.6 mg/dL and vitamin D 22 ng/mL at the first visit; cholecalciferol starts today |
| Imaging | Bone density (DXA) with FRAX | Baseline before androgen deprivation, then every 1 to 2 years | Completed today | Femoral neck T-score -2.1; L1 to L4 -1.4; FRAX hip 3.4 percent, major osteoporotic 13 percent |
| Imaging | Staging: CT, bone scan and PSMA PET/CT | At diagnosis | Up to date | Completed in the past ten days; low volume on conventional imaging; PSMA PET/CT concordant |
| Examination | Blood pressure and cardiovascular assessment | Every visit on androgen deprivation | Completed today | 142/86 mm Hg; no chest pain or breathlessness |
| Examination | Neurological check for spinal cord compression | Every visit with spinal metastases | Completed today | Normal leg strength, sensation and reflexes; no bladder or bowel change |
| Survey | Distress and depression screen (PHQ-2) | At diagnosis and at intervals | Completed today | PHQ-2 score 1 |
| Survey | Pain score | Every visit with symptomatic metastases | Completed today | 5 of 10 at worst on acetaminophen, down from 6 |
| Survey | Urinary symptoms (IPSS) | Baseline before treatment, then every follow-up visit | Up to date | IPSS 17 at the first visit; unchanged |
| Survey | Sexual function | Baseline before treatment and periodically | Completed today | Reviewed before androgen deprivation; loss of libido and erections explained |
| Survey | Cognition | Periodically on androgen deprivation | Due | Mini-Cog at the annual wellness visit |
| Medication safety | Testosterone flare protection | When starting a GnRH agonist with bone metastases | Completed today | Apalutamide starts today, one week before leuprolide |
| Medication safety | Drug interactions with apalutamide | When starting and with any new medicine | Completed today | Strong CYP3A4 inducer: amlodipine levels expected to fall; blood pressure check in four weeks |
| Medication safety | Falls and fracture risk on apalutamide | Every visit on androgen deprivation | Completed today | No falls; counseled on rugs, lighting and night-time walking |
| Referral | Medical oncology (genitourinary) | Once, then through treatment | Completed today | Seen today; recommendations in the consultation note |
| Referral | Germline genetic testing with counseling | Once, for metastatic disease | Completed today | Counseled and blood drawn today; result in two to three weeks |
| Referral | Radiation oncology for radiotherapy to the prostate | Once | Ordered | Planning visit in about four weeks |
| Self-management | Physical activity, calcium intake, no tobacco, and care in Spanish | Every visit | Completed today | Walking as pain allows; calcium from food; written plan in Spanish |

## Goal progress

- Diagnosis, staging and a shared treatment decision within three weeks of the first visit. Outcome by 2026-06-15: Biopsy, CT, bone scan and PSMA PET/CT within ten days; apalutamide started at the consultation two weeks after intake. **S**
- Bone pain controlled, with a pain score of 2 or less and sleep restored. In progress; target 2026-07-13. **S**
- PSA of 0.2 ng/mL or less within about seven months of starting treatment. In progress; target 2026-09-14. **S**
- Blood pressure below 130/80 mm Hg on androgen deprivation. In progress; target 2026-10-05. **S**
- Protect bone health: 25-hydroxyvitamin D of 30 ng/mL or more, calcium from food, weight-bearing exercise, and a bone-protective drug for high fracture risk. In progress; target 2026-10-05. **S**
- Keep his morning writing and his official duties through treatment. In progress; target 2026-10-05. **S**

## Medication changes

- Started: Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without food **S**
- Started: Cholecalciferol (vitamin D3) 2000 units (0.05 mg) oral tablet, one tablet daily **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026), National Comprehensive Cancer Network
- Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026), American Urological Association and Society of Urologic Oncology
- ERLEADA (apalutamide) tablets: prescribing information (2026), Janssen Products, LP, via DailyMed (National Library of Medicine)
- CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026), Aether Forge

## Follow-up

- Leuprolide at the oncology clinic in one week. Dental examination before the next visit. Review in four weeks with PSA, testosterone, chemistry, vitamin D and blood pressure. **S**
- Next scheduled visit 2026-07-13: four-week review on apalutamide and leuprolide: early PSA response, testosterone, blood pressure, pain, the dental check and the first denosumab dose, and the radiotherapy plan. **S**
